Eradivir’s EV25: Revolutionary Therapy Slashes Advanced-Stage Influenza Viral Loads Faster Than Current Treatments

Eradivir’s EV25: Revolutionary Therapy Slashes Advanced-Stage Influenza Viral Loads Faster Than Current Treatments

November 20, 2024 Catherine Williams - Chief Editor Health

Eradivir and Its Antiviral Drug EV25

Eradivir is a preclinical biotech company that has created a new antiviral treatment, EV25. This drug shows promise in reducing lung viral loads of advanced-stage influenza more quickly and effectively than existing treatments.

How EV25 Works

EV25 is a bispecific small molecule given as a single intranasal dose. It can eliminate the detectable influenza virus within 24 hours and remains effective for up to 96 hours after infection. This broader efficacy makes it a potential game changer in influenza treatment.

Research and Development

Philip Low, an expert in drug discovery at Purdue University, developed the platform for EV25. He serves as Eradivir’s chief scientific officer. He reported the new treatment to Purdue’s technology office, which has secured patents and licensed the technology to Eradivir for further development.

Current Influenza Threats

Imrul Shahriar, a scientist at Eradivir, emphasized that influenza remains a significant health threat. Current FDA-approved drugs work best when given early. They are less effective in severe cases. Shahriar points out that many people remain unvaccinated, resulting in millions of illnesses and tens of thousands of deaths yearly in the U.S.

Reasons for Continued Influenza Risk

  1. Only about 50% of the U.S. population is vaccinated.
  2. Current vaccines have varying effectiveness (19% to 60%).
  3. Many flu strains mutate, compromising the effectiveness of existing therapies.
  4. Pandemics can arise from new strains that spread from animals to humans.

Testing EV25

Shahriar, who earned his PhD from Low’s lab, noted that EV25 reduces viral loads by lowering inflammatory markers and protecting lung tissue. This combination of immunotherapy and chemotherapy offers a new approach to treating severe influenza infections.

Upcoming Trials

EV25 has received approval for a Phase 1 human trial in Europe and Belgium, expected to complete early next year. Following this, a Phase 2a trial will start to assess safety and effectiveness, with data available by July 2025.

Presentation at OPTIONS XII

During the OPTIONS XII conference in Brisbane, Australia, Jeffery Nielsen from Eradivir presented findings about EV25. This presentation won the Best in Clinical Science and Vaccinology award. The conference discussed both EV25 and a new treatment for respiratory syncytial virus (RSV), both developed from Purdue’s BAiT platform.

Eradivir aims to make significant strides in treating influenza and RSV with these innovative therapies.